

Company Facts Sheet

Personalized Cancer Immunotherapy



Democratizing CAR-T therapies for all cancer patients

Company Profile


T-CURX is an early-stage, Würzburg & Munich-based, German Biotech company focused on developing next generation CAR-T cell therapies, based on cost-effective and scalable CAR-T technologies developed in the CAR-T lab of Prof. Michael Hudecek, University of Würzburg. At T-CURX we leverage a novel, non-viral CAR-T technology together with advanced engineering solutions for point-of-care CAR-T manufacturing to develop an internal pipeline of innovative CAR-T therapies, which can be commercialized more cost-effectively and more broadly. T-CURX has the vision to democratize CAR-T therapies for all cancer patients. This includes delivering more cost-effective CAR-T therapies also for existing CAR-T products ("CAR-T similars") in all countries of the world, incl. countries currently excluded from these therapies (e.g. in Africa, South America and parts of Asia).

Proprietary IP-protected Technology Platform

T-CURX has strong know-how in non-viral CAR-T manufacturing and has built a strong IP portfolio consisting of 8 patent families protecting the company's technologies and product candidates.

In addition, we focus on combining T-CURX highly scalable and cost-effective CAR-T manufacturing technologies with advanced engineering solutions allowing simple point-of-care (at the bedside of the patient) CAR-T manufacturing.

We also aim to implement this technology for "CAR-T similar" products in clinical centers of countries outside of Europe and US (incl. Africa, Middle- and South America, as well as Asian countries) where CAR therapies are not available or affordable for patients.



Leadership and Board of Directors

T-CURX is led by the company's co-founder Ulf Grawunder, PhD, a serial entrepreneur with a proven track record in company building (4-Antibody, NBE-Therapeutics) and deal making (both companies had various commercial deals and were brought to an attractive exit). His expertise is matched by a management team and Board of Directors with complimentary skills and established networks both in Europe and the US. T-CURX is also supported by its Scientific Advisory Board, a highly regarded network of leading experts that serve as external advisors and investigators on clinical trials.

Management

- Ulf Grawunder, PhD, CEO & Co-Founder
- Michael Hudecek, MD, Co-Founder & CMO
- Marion Jung, PhD, COO
- Karl Schumacher, MD, CCO
- Caroline Burger, PhD, Global Head BD
- Jan Van den Brulle, PhD, Head R&D
- Christian Söllner, General Counsel

Chairman of the Board

Hanspeter Gerber, PhD (US)

Scientific Advisory Board

- Michael Hudecek, Prof., MD, Co-Founder (D)
- Christoph Rader, Prof., PhD, Co-Founder (US)
- Hermann Einsele, Prof., MD (D)
- Cameron Turtle, Prof., MD, PhD (AU)

CAR-T specialists

- Sabrina Prommersberger, PhD
- Thomas Nerreter, PhD

Company at a glance

- T-CURX team with strong track record in clinical & business translation
- Sleeping Beauty transposon-based, virus-free gene transfer offers unparalleled scalability and efficiency
- T-CURX Sleeping Beauty transposon-based CAR-T manufacturing already clinically validated in patients in Phase I clinical trial
- T-CURX non-viral CAR-T manufacturing currently positioned for supply of "CAR-T similar" product in first non-EU country.
- IP portfolio (Technology & Pipeline) of 8 patent families exclusive to T-CURX
- 2nd CAR-T program in AML is ready for clinical trial application (in 2024)

T-CURX GmbH

Innovation and Founder Centre
Friedrich-Bergius-Ring 15
97076 Würzburg
Deutschland

P: +49-(0)-931-250-99-712

E: info@t-curx.com

W: www.t-curx.com



Jan 2024

Company Fact Sheet

Personalized Cancer Immunotherapy

T-CURX

Company Strategy

T-CURX will develop its own clinical candidates towards clinical proof-of-concept in several indications with the ultimate aim of advancing its proprietary technologies into development against additional cancer indications including solid tumors. This may ultimately make the transposon technology with its manufacturing process the future gold-standard in CAR-T cell therapy. In addition, T-CURX offers selected partners the opportunity to discover and develop additional therapies based on its technological platforms.

Partnerships and Grant-Funded Collaborations

Since its foundation in 2017, T-CURX secured non-dilutive funding in a total volume of over € 1.6 m through the award of several research grants. Amongst them are 2 German grants from BMBF and 3 EU grants (CARAMBA/RIA, imSAVAR/IMI, T2EVOLVE/IMI) with funding rates spanning from 50 % to 100 % for all EU grants. These consortia consist in total of more than 50 partners ranging from big pharma to academia and other institutions.

2023 – 2026 Development Plan and Value Inflection Points

T-CURX has established a differentiated target portfolio with first- and best-in-class potential and seeks funding for a 4 years' time frame to reach several critical value inflection points:

- **2023:** SLAMF7 Ph1 trial ongoing, data readout in 2024. CTA in preparation for 2nd program in AML, pipeline programs 3, 4 initiated
- **2024:** 2 Ph1 trials ongoing (SLAMF7 & Target 2 programs) 2 additional target programs IND ready
- **2025:** 2 Ph 2a trials ongoing (SLAMF7 1, Target2), 2 additional Ph 1 trials started (first early exit option)
- **2026:** 4 CAR-T programs in Ph 1/2a clinical trials, preparations for exit (M&A or IPO) underway

Investor Base and Financial Status

T-CURX' company runway is secured until Q2 2024 by strong commitments of existing shareholders, mostly European/US Single Family Offices. The company starts a fundraising campaign for a Preferred Series A Equity Financing Round with institutional European and US investors in 2023.

Recent Financial Highlights in the CAR-T Sector

- **June 2022, Cellpoint:** acquisition by Galapagos to accelerate access to next-generation cell therapies (€ 125m upfront and € 100m on milestones)
- **Sept 2022, Arsenal Biosciences:** \$ 220m Pref. Series B round, discovery collaboration with Genentech (\$ 70m upfront and undisclosed amount for R&D, development and commercial milestones)
- **March 2023, CARGO Therapeutics:** Spin-off of Stanford University, \$ 200m Series A financing for clinical development of CD19/CD22 dual CAR-T therapies
- **Aug 2023: Cellares:** \$ 255m Series C financing of Cell Therapy/CAR-T CDMO

T-CURX Recognition in the CAR-T Sector

- 2015: German M4 award in recognition of IP property base and business concept
- 2018: Horizon 2020 EU translational project CARAMBA for translation into Ph I clinical trials by utilizing proprietary virus-free transposon-based CAR-T technology in multiple myeloma
- 2021: Scientific advice meeting with German Paul-Ehrlich-Institute for T-CURX CAR-T cell program in Acute Myeloid Leukemia
- 2021: FDA approval for Breyanzi® marketed by Bristol Myers Squibb (Prof. Michael Hudecek co-inventor and author of key patent)

Active Pharma Players in the CAR-T Space:

